DEPARTMENT OF HEALTH AND HUMAN SERVICES 11/27/2013
|
|
|
- Tamsyn Annabel Hunter
- 10 years ago
- Views:
Transcription
1 ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER BETHANY REHAB & H (X4) (X1) PROVER/SUPPLIER/LIA ENTIFIATION NUMBER: SUMMARY STATEMENT OF DEFIIENIES (EAH DEFIIENY MUST BE PREEDED BY FULL REGULATORY OR LS ENTIFYING INFORMATION) (X2) MULTIPLE ONSTRUTION (X3) SURVEY OMPLETED DEFIIENY) F 309 ontinued From page 8 F 309 On 10/25/13 at 11:30 AM, Z2 (Gynecologist) stated, R1 "was in awful shape when (she) arrived. She was clammy, pale, and dying. 911 was called before I walked into the room (to examine R1)." The facilty should have taken vitals. It could have been an acute (sudden) change after R1 left the facility (between 12:45 PM and 1:00 PM. Z2's progress note dated 9/3/13 documents, "Pt (R1) found to be agonal (near death), very pale... Paramedics called. Son called... Pt (R1) taken to (local hospital Emergency Room). Pt (R1) without HR (heart rate) in ambulance as it (the ambulance) was leaving." Emergency room progress note dated 9/3/13 states, "This patient was brought to the emergency department via (local) EMS (Emergency Medical Services). She (R1) was DOA (Dead on Arrival) at a local physician's office. This writer notified notified coroner of body's arrival and the events leading to her (R1's) arrival..." R1's certification of death record dated 9/3/13 states, "ause of Death - Shock, ongestive Heart Failure, Vaginal Bleeding." The manufacture guidelines (dated 8/2013) states, "(Warnings and Precautions) Risk of bleeding: XARELTO can cause serious and fatal bleeding. Promptly evaluate signs and symptoms of blood loss." and "Promptly evaluate any signs or symptoms of blood loss and consider the need for blood replacement. Discontinue XARELTO in patients with active pathological hemorrhage." (p 1-3) FINAL OBSERVATIONS FORM MS-2567(02-99) Previous Versions Obsolete Event : W2UZ11 Facility : IL If continuation sheet Page 9 of 16
2 ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER BETHANY REHAB & H (X4) (X1) PROVER/SUPPLIER/LIA ENTIFIATION NUMBER: SUMMARY STATEMENT OF DEFIIENIES (EAH DEFIIENY MUST BE PREEDED BY FULL REGULATORY OR LS ENTIFYING INFORMATION) (X2) MULTIPLE ONSTRUTION (X3) SURVEY OMPLETED DEFIIENY) ontinued From page 9 STATEMENT OF LIENSURE VIOLATIONS h) b) c) d)3) b)1) b)2) a Section Medical are Policies h) The facility shall notify the resident's physician of any accident, injury, or significant change in a resident's condition that threatens the health, safety or welfare of a resident, including, but not limited to, the presence of incipient or manifest decubitus ulcers or a weight loss or gain of five percent or more within a period of 30 days. The facility shall obtain and record the physician's plan of care for the care or treatment of such accident, injury or change in condition at the time of notification Section General Requirements for Nursing and Personal are : b) The facility shall provide the necessary care and services to attain or maintain the highest practicable physical, mental, and psychological well-being of the resident, in accordance with each resident's comprehensive resident care plan. Adequate and properly supervised nursing care and personal care shall be provided to each resident to meet the total nursing and personal care needs of the resident. c) Each direct care-giving staff shall review and FORM MS-2567(02-99) Previous Versions Obsolete Event : W2UZ11 Facility : IL If continuation sheet Page 10 of 16
3 ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER BETHANY REHAB & H (X4) (X1) PROVER/SUPPLIER/LIA ENTIFIATION NUMBER: SUMMARY STATEMENT OF DEFIIENIES (EAH DEFIIENY MUST BE PREEDED BY FULL REGULATORY OR LS ENTIFYING INFORMATION) (X2) MULTIPLE ONSTRUTION (X3) SURVEY OMPLETED DEFIIENY) ontinued From page 10 be knowledgeable about his or her residents' respective resident care plan. d) Pursuant to subsection (a), general nursing care shall include, at a minimum, the following and shall be practiced on a 24-hour, seven-day-a-week basis: 3) Objective observations of changes in a resident's condition, including mental and emotional changes, as a means for analyzing and determining care required and the need for further medical evaluation and treatment shall be made by nursing staff and recorded in the resident's medical record. Section Supervision of Nursing Services b) The DON shall supervise and oversee the nursing services of the facility, including: 1) Assigning and directing the activities of nursing service personnel. 2) Overseeing the comprehensive assessment of the residents' needs, which include medically defined conditions and medical functional status, sensory and physical impairments, nutritional status and requirements, psychosocial status, discharge potential, dental condition, activities potential, rehabilitation potential, cognitive status, and drug therapy. Section Abuse and Neglect a) An owner, licensee, administrator, employee or agent of a facility shall not abuse or neglect a resident. FORM MS-2567(02-99) Previous Versions Obsolete Event : W2UZ11 Facility : IL If continuation sheet Page 11 of 16
4 ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER BETHANY REHAB & H (X4) (X1) PROVER/SUPPLIER/LIA ENTIFIATION NUMBER: SUMMARY STATEMENT OF DEFIIENIES (EAH DEFIIENY MUST BE PREEDED BY FULL REGULATORY OR LS ENTIFYING INFORMATION) (X2) MULTIPLE ONSTRUTION (X3) SURVEY OMPLETED DEFIIENY) ontinued From page 11 These requirements were not met as evidenced by: Based on interview and record review the facility failed to provide necessary care and services by not conducting a comprehensive assessment including vital signs. The facility failed to seek emergency treatment for a resident with continued bleeding as her condition worsened over five and one half hours. These failures contributed to R1 showing signs and symptoms of shock. This applies to 1 of 4 residents (R1) reviewed for care abd services in the sample of 4. The findings include: The August 2013 Physician Order summary shows R1 was taking Aspirin and was started on Xarelto (blood thinner) on 8/12/13 for Atrial Fibrillation. R1's Plan of are (updated 9/4/13) states, "The resident is on Anticoagulant therapy; Monitor/document/report to Nurse/Dr. s/sx (signs/symptoms) of anticoagulation complications: blood tinged or frank blood in urine, black tarry stools, dark or bright red blood in stools, sudden severe headaches, nausea, vomiting, diarrhea, muscle joint pain, lethargy, bruising, blurred vision, SOB (Short of Breath), Loss of appetite, sudden changes in mental status, significant or sudden changes in v/s (vital signs)..." On 11/26/13 at 1:30 PM, Z3 (R1's Power of Attorney for Healthcare) stated, "When we went to the facility there were multiple gowns with FORM MS-2567(02-99) Previous Versions Obsolete Event : W2UZ11 Facility : IL If continuation sheet Page 12 of 16
5 ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER BETHANY REHAB & H (X4) (X1) PROVER/SUPPLIER/LIA ENTIFIATION NUMBER: SUMMARY STATEMENT OF DEFIIENIES (EAH DEFIIENY MUST BE PREEDED BY FULL REGULATORY OR LS ENTIFYING INFORMATION) (X2) MULTIPLE ONSTRUTION (X3) SURVEY OMPLETED DEFIIENY) ontinued From page 12 blood on them. Her (R1's) roommate said she had been bleeding for several days." On 10/24/13 at 2:00 PM, E4 (Transport NA, ertified Nursing Assistant) said between 8:00 and 9:00 AM, The nurse (E3,Registered Nurse) told me R1 was having some vaginal bleeding. E3 stated R1 needed to be transported for an ultrasound (requested by Gynecologist) and then to her Gynecologist appointment. E4 continued. "I spoke with (R1) before leaving for the ultrasound. She looked sick; she had a spit pan and tissues. She looked tired, and had no energy... At the hospital, the condition of (R1) declined. During the ultrasound (R1's) breathing increased; it was a big difference... We got back (to the facility) around lunchtime... I told the nurse immediately, there was something wrong with (R1's) breathing, (R1's) color had changed. She (R1) was cold, clammy, and had wet skin. I took (R1) to her room (at 12:00 PM) and she (R1) was by herself (until we left for her Gynecologist appointment at 1:00 PM)'. On 10/25/13 at 10:20 AM, E3 (RN) stated, "I saw (R1) about 7:45 AM (on the 9/3/13). (R1) was in her bathroom. One of her aides had called me to her (R1's) room for bleeding. I observed the blood; (there was a) fairly large amount (of blood). It covered the wheelchair, and there were many clots. There was about 500 ml of blood; there was a lot of blood... (R1) declined any pain. I looked at her perineum (area between the vagina and anus) and R1 was trickling blood... I couldn't identify the source. I called (Z1) physician and told him she (R1) was not feeling well and complained of nausea...i explained there was a lot of blood. I had no further communication with (Z1) that day... R1 left for the FORM MS-2567(02-99) Previous Versions Obsolete Event : W2UZ11 Facility : IL If continuation sheet Page 13 of 16
6 ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER BETHANY REHAB & H (X4) (X1) PROVER/SUPPLIER/LIA ENTIFIATION NUMBER: SUMMARY STATEMENT OF DEFIIENIES (EAH DEFIIENY MUST BE PREEDED BY FULL REGULATORY OR LS ENTIFYING INFORMATION) (X2) MULTIPLE ONSTRUTION (X3) SURVEY OMPLETED DEFIIENY) ontinued From page 13 (ultrasound) at approximately 10:40 AM. She (R1) returned at 12:15 PM, I put pulse ox (pulse oximertry), and it was normal. I listened to her lungs. She was a little cold. It was reported to me (R1's) breathing was off... I remember her (R1) being a little bit wet. I didn't think at that time the change was significant. Vitals were not taken (after R1 returned from ultrasound)". E3 stated she did not call R1's primary physician after R1 returned from the ultrasound. E3 said she never took R1's vitals; That day R1's vitals were taken once, by a NA before R1 left for her ultrasound appointment at 10:40 AM. On 10/24/13 at 2:00 PM, E3 continued, We left shortly after 1:00 PM. The nurse at the Gynecologist's office took R1's blood pressure and it was 90/50. R1's nursing note dated 9/3/13 at 3:41 PM, states, "Upon shift change nurse (at 7:00 AM) was called into resident's (R1) room to inspect bleeding from perineum area, nausea and vomiting. Nurse witnessed blood with numerous clots on residents wheelchair. Vitals taken at 1040 AM... MD (Z1, Primary are Physician) notified and ordered for resident to be refereed to OB/GYN, due to bleeding being a chronic issue. OB/GYN called and required pelvic X-ray before he (Z2, Gynecologist) could see resident (R1). MD office (Z1) notified and agreed to order pelvic exam. When resident returned from pelvic exam at 1215 PM, the nurse called OB/GYN (Z2's office) to schedule appt. (appointment). Appt was made for 1:15 PM, Resident left facility at 1:00 PM." On 10/25/13 at 9:15 AM, E2 (Director of Nursing) was asked when staff report to the nurse that a FORM MS-2567(02-99) Previous Versions Obsolete Event : W2UZ11 Facility : IL If continuation sheet Page 14 of 16
7 ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER BETHANY REHAB & H (X4) (X1) PROVER/SUPPLIER/LIA ENTIFIATION NUMBER: SUMMARY STATEMENT OF DEFIIENIES (EAH DEFIIENY MUST BE PREEDED BY FULL REGULATORY OR LS ENTIFYING INFORMATION) (X2) MULTIPLE ONSTRUTION (X3) SURVEY OMPLETED DEFIIENY) ontinued From page 14 resident has a change in breathing, color, and is cold/clammy, or wet, how should the nurse respond. E2 stated, "I would expect the nurse assess the patient ASAP (As soon as possible). The nurse should go directly to assess the patient, and provide any treatment we could... Vital signs and a symptom specific assessment should be completed, and the primary (care physician) should be called to report the change in condition." On 10/25/13 at 10:45 AM, Z1 (Primary Physician) stated, "I was called because (R1) was having vaginal bleeding. (At that time), (R1) had normal vital signs." Z1 continued, when it was reported that R1 had become cold, clammy, and pale in color, "The nurse should have checked (R1's) heart rate and blood pressure. If R1's blood pressure was low or if (R1) she showed signs of a change in condition, (The nurse) should have called me again. This didn't happen suddenly. I don't know if the lack of assessment contributed to the incident. I don't think it was Hypovolemic (low-blood volume) Shock". On 10/25/13 at 11:30 AM, Z2 (Gynecologist) stated, R1 "was in awful shape when (she) arrived. She was clammy, pale, and dying. 911 was called before I walked into the room (to examine R1)." The facilty should have taken vitals. It could have been an acute (sudden) change after R1 left the facility (between 12:45 PM and 1:00 PM. Z2's progress note dated 9/3/13 documents, "Pt (R1) found to be agonal (near death), very pale... Paramedics called. Son called... Pt (R1) taken to (local hospital Emergency Room). Pt (R1) without HR (heart rate) in ambulance as it (the FORM MS-2567(02-99) Previous Versions Obsolete Event : W2UZ11 Facility : IL If continuation sheet Page 15 of 16
8 ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER BETHANY REHAB & H (X4) (X1) PROVER/SUPPLIER/LIA ENTIFIATION NUMBER: SUMMARY STATEMENT OF DEFIIENIES (EAH DEFIIENY MUST BE PREEDED BY FULL REGULATORY OR LS ENTIFYING INFORMATION) (X2) MULTIPLE ONSTRUTION (X3) SURVEY OMPLETED DEFIIENY) ontinued From page 15 ambulance) was leaving." Emergency room progress note dated 9/3/13 states, "This patient was brought to the emergency department via (local) EMS (Emergency Medical Services). She (R1) was DOA (Dead on Arrival) at a local physician's office. This writer notified notified coroner of body's arrival and the events leading to her (R1's) arrival..." R1's certification of death record dated 9/3/13 states, "ause of Death - Shock, ongestive Heart Failure, Vaginal Bleeding." The manufacture guidelines (dated 8/2013) states, "(Warnings and Precautions) Risk of bleeding: XARELTO can cause serious and fatal bleeding. Promptly evaluate signs and symptoms of blood loss." and "Promptly evaluate any signs or symptoms of blood loss and consider the need for blood replacement. Discontinue XARELTO in patients with active pathological hemorrhage." (p 1-3) A FORM MS-2567(02-99) Previous Versions Obsolete Event : W2UZ11 Facility : IL If continuation sheet Page 16 of 16
DEPARTMENT OF HEALTH AND HUMAN SERVICES
DEPARTMENT OF HEALTH AND HUMAN SERVIES ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO. 0938-0391 (X2) MULTIPLE ONSTRUTION STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER SOUTH SHORE
DEPARTMENT OF HEALTH AND HUMAN SERVICES 05/22/2013. F 323 Continued From page 3 F 323
ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO. 0938-0391 STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER WAY-FAIR NURSING & REHAB ENTER (X4) (X1) PROVER/SUPPLIER/LIA ENTIFIATION NUMBER:
DEPARTMENT OF HEALTH AND HUMAN SERVICES. F 315 Continued From page 17 F 315
DEPARTMENT OF HEALTH AND HUMAN SERVIES ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO. 0938-0391 (X2) MULTIPLE ONSTRUTION STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER EVERGREEN HEALTH
DEPARTMENT OF HEALTH AND HUMAN SERVICES. F 324 Continued From page 6 F 324
N DEPARTMENT OF HEALTH AND HUMAN SERVIES ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO. 0938-0391 (X2) MULTIPLE ONSTRUTION STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER BETHAN HEALTH
DEPARTMENT OF HEALTH AND HUMAN SERVICES. F9999 Continued From page 8 F9999
ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO. 0938-0391 (X2) MULTIPLE ONSTRUTION STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER WEST RGE REHABILITATION ENTER (X4) (X1) PROVER/SUPPLIER/LIA
Illinois Department of Public Health STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION C 04/26/2015. Statement of Licensure Violations:
(X1) PROVER/SUPPLIER/LIA ENTIFIATION NUMBER: (X3) SURVEY D NAME OF PROVER OR SUPPLIER (X4) REGULATORY OR LS ENTIFYING INFORMATION) Final Observations Statement of Licensure Violations: 300.610a) 300.1210b)
PRINTED: 07/09/2013 FORM APPROVED CENTERS FOR MEDICARE & MEDICAID SERVICES OMB NO. 0938-0391 (X2) MULTIPLE CONSTRUCTION A.
CENTERS FOR MEDICARE & MEDICA SERVICES OMB NO. 0938-0391 (X1) PROVER/SUPPLIER/CLIA ENTIFICATION NUMBER: (X3) SURVEY NAME OF PROVER OR SUPPLIER (X4) FINAL OBSERVATIONS LICENSURE VIOLATIONS: 300.610)a) 300.1210)a)
PRINTED: 08/01/2006 FORM APPROVED CENTERS FOR MEDICARE & MEDICAID SERVICES OMB NO. 0938-0391 A. BUILDING Y N
DEPARTMENT OF HEALTH AND HUMAN SERVIES ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO. 0938-0391 (X2) MULTIPLE ONSTRUTION STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER ARLINGTON REHAB
Illinois Department of Public Health STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION. Statement of LICENSURE Violations
(X1) PROVER/SUPPLIER/CLIA ENTIFICATION NUMBER: (X3) SURVEY D NAME OF PROVER OR SUPPLIER (X4) SUMMARY REGULATORY OR LSC ENTIFYING INFORMATION) PROVER'S PLAN OF CORRECTION Final Observations Statement of
Illinois Department of Public Health STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION. Investigation of Incident Report Investigation of 7/6/13.
(X1) PROVER/SUPPLIER/CLIA ENTIFICATION NUMBER: (X3) SURVEY D NAME OF PROVER OR SUPPLIER (X4) SUMMARY REGULATORY OR LSC ENTIFYING INFORMATION) PROVER'S PLAN OF CORRECTION Z 000 COMMENTS Z 000 Investigation
DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR MEDICARE & MEDICA SERVICES OMB NO. 0938-0391 (X1) PROVER/SUPPLIER/CLIA ENTIFICATION NUMBER: B. WING (X3) SURVEY NAME OF PROVER OR SUPPLIER (X4) REGULATORY OR LSC ENTIFYING INFORMATION) PROVER'S
DEPARTMENT OF HEALTH AND HUMAN SERVICES. Y W 186 Continued From page 29 W 186 Y. taking R1 on rounds and /or into client room with them.
DEPARTMENT OF HEALTH AND HUMAN SERVIES ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO. 0938-0391 (X2) MULTIPLE ONSTRUTION STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER LINTON MANOR
DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR MEDICARE & MEDICA SERVICES OMB NO. 0938-0391 (X1) PROVER/SUPPLIER/CLIA ENTIFICATION NUMBER: (X3) SURVEY NAME OF PROVER OR SUPPLIER (X4) REGULATORY OR LSC ENTIFYING INFORMATION) PROVER'S PLAN
DEPARTMENT OF HEALTH AND HUMAN SERVICES 11/09/2012
CENTERS FOR MEDICARE & MEDICA SERVICES OMB NO. 0938-0391 (X1) PROVER/SUPPLIER/CLIA ENTIFICATION NUMBER: (X3) SURVEY NAME OF PROVER OR SUPPLIER (X4) REGULATORY OR LSC ENTIFYING INFORMATION) PROVER'S PLAN
Safety Information Card for Xarelto Patients
Safety Information Card for Xarelto Patients 15mg Simply Protecting More Patients 20mg Simply Protecting More Patients Keep this card with you at all times Present this card to every physician or dentist
What You Need to KnowWhen Taking Anticoagulation Medicine
What You Need to KnowWhen Taking Anticoagulation Medicine What are anticoagulant medicines? Anticoagulant medicines are a group of medicines that inhibit blood clotting, helping to prevent blood clots.
Anticoagulation in Atrial Fibrillation Patient information
Anticoagulation in Atrial Fibrillation Patient information RSBAY013 Anticoag A5 V2.indd 1 21/02/2014 17:13 Introduction This leaflet will help you understand your new medicine. Your new medicine is commonly
FAQs about Warfarin (brand name Coumadin )
FAQs about Warfarin (brand name Coumadin ) What is warfarin? Warfarin is the most commonly used anticoagulant in the US. An anticoagulant is a drug used to prevent unwanted and harmful blood clots. Although
Southwest General Surgical Associates General & Vascular Surgery 8230 Walnut Hill Lane Suite 408 Dallas, TX 75231 Phone-214)369-5432 Fax-214)369-5591
Southwest General Surgical Associates General & Vascular Surgery 8230 Walnut Hill Lane Suite 408 Dallas, TX 75231 Phone-214)369-5432 Fax-214)369-5591 Andres U. Katz, M.D. Richard S. Anderson, M.D. G. Thomas
COALINGA STATE HOSPITAL. Effective Date: August 31, 2006
COALINGA STATE HOSPITAL NURSING POLICY AND PROCEDURE MANUAL SECTION Emergency Procedures POLICY NUMBER: 715 Effective Date: August 31, 2006 SUBJECT: EMERGENCY CARE OF HEMORRHAGE 1. PURPOSE: The management
Guide to Dabigatran, Rivaroxaban and Apixaban
Page 1 of 8 Guide to Dabigatran, Rivaroxaban and Apixaban Medicines to Prevent Blood Clots If you are deaf or hard of hearing, please let us know. We provide many free services including sign language
XARELTO BLEEDING RISKS AND POTENTIALLY FATAL SIDE EFFECTS
XARELTO BLEEDING RISKS AND POTENTIALLY FATAL SIDE EFFECTS 1 In 2011, a new anticoagulant drug was approved by the U.S. Food and Drug Administration (FDA). The new drug Xarelto was marketed as a more convenient
CAMARILLO AQUATICS AND REHABILITATION SERVICES
CAMARILLO AQUATICS AND REHABILITATION SERVICES Last Name First M.I. Address Apt.# City State Zip Code Phone # SS# Date of Birth Sex M F Driver s License # Marital Status: S M D W Spouse s Name How did
Service Agreement SERVICE AGREEMENT
SERVICE AGREEMENT Name of Client: Service Agreement : Address: of Referral or Initial Request for Service: of Initial Contact: Is Client MF/MC? Yes [ ] No [ ] Client s description of Services needed/specific
ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT)
ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT) Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet
DEPARTMENT OF HEALTH AND HUMAN SERVICES
DEPARTMENT OF HEALTH AND HUMAN SERVIES ENTERS FOR MEDIARE & MEDIA SERVIES OMB NO. 0938-0391 (X2) MULTIPLE ONSTRUTION STATEMENT OF DEFIIENIES AND PLAN OF ORRETION NAME OF PROVER OR SUPPLIER EAST PEORIA
A PATIENT S GUIDE TO DEEP VEIN THROMBOSIS TREATMENT
A PATIENT S GUIDE TO DEEP VEIN THROMBOSIS TREATMENT This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk
ORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE)
ORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE) Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet has
Venous Thrombosis and Pulmonary Embolism Treatment with Rivaroxaban
Venous Thrombosis and Pulmonary Embolism Treatment with Rivaroxaban Information for patients and families Read this booklet to learn: about venous thrombosis and pulmonary embolism how the medicine Rivaroxaban
Lighthouse IF YOU WERE THE DRIVER OF YOUR OWN VEHICLE, SOMEONE ELSE S VEHICLE OR A PASSENGER IN THE VEHICLE, ANSWER THIS SECTION COMPLETELY.
Lighthouse Chiropractic IF YOU WERE THE DRIVER OF YOUR OWN VEHICLE, SOMEONE ELSE S VEHICLE OR A PASSENGER IN THE VEHICLE, ANSWER THIS SECTION COMPLETELY. Your Auto Insurance Company Name Address Policy
what is warfarin? Treatment with Warfarin (Coumadin ) What is warfarin?
What is warfarin? Warfarin sodium (Coumadin ) is a medication that works as an anti-coagulant. Anti means against and coagulant refers to blood clotting. An anticoagulant helps to prevent clots from forming
A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation
Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation PATIENT EDUCATION GUIDE What is atrial fibrillation? Atrial fibrillation
Sudden dizziness, trouble walking, loss of balance or coordination
rivaroxaban (Xarelto) Patient Education Information Sheet Veterans Health System Pharmacy Service 119 What is rivaroxaban (Xarelto)? A new anticoagulant ( blood thinner ) that reduces the risk of stroke
Treatment with Rivaroxaban
UW MEDICINE PATIENT EDUCATION Treatment with Rivaroxaban Xarelto This handout explains the medicine rivaroxaban, a drug that helps prevent blood clots. What is rivaroxaban? Rivaroxaban (brand name Xarelto)
Planning: Patient Goals and Expected Outcomes The patient will: Remain free of unusual bleeding Maintain effective tissue perfusion Implementation
Obtain complete heath history including allergies, drug history and possible drug Assess baseline coagulation studies and CBC Assess for history of bleeding disorders, GI bleeding, cerebral bleed, recent
UW MEDICINE PATIENT EDUCATION. Xofigo Therapy. For metastatic prostate cancer. What is Xofigo? How does it work?
UW MEDICINE PATIENT EDUCATION Xofigo Therapy For metastatic prostate cancer This handout explains how the drug Xofigo is used to treat metastatic prostate cancer. What is Xofigo? Xofigo is a radioactive
ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR ATRIAL FIBRILLATION
ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR ATRIAL FIBRILLATION Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet has
Emergency Care for Patients of The James
PATIENT EDUCATION patienteducation.osumc.edu Emergency Care for Patients of The James Emergency Care During and After Treatment Here are guidelines about when and how to report problems that you may have
Women s Continence and Pelvic Health Center
Women s Continence and Pelvic Health Center Committed to Caring 580-590 Court Street Keene, New Hampshire 03431 (603) 354-5454 Ext. 6643 URINARY INCONTINENCE QUESTIONNAIRE The purpose of this questionnaire
Diabetes Hypoglycemia/Hyperglycemia Reaction
Diabetes Hypoglycemia/Hyperglycemia Reaction Hypoglycemic Reaction (Insulin Shock) A. Hypoglycemic reactions (insulin reactions) should be treated according to current nursing and medical recommendations.
Caring for the Client with Heart Failure
Peak Development Resources, LLC P.O. Box 13267 Richmond, VA 23225 Phone: (804) 233-3707 Fax: (804) 233-3705 After reading the newsletter, the home health aide should be able to: 1. Define heart failure.
Get the Facts About. Disease
Get the Facts About TB TUBERCULOSIS Disease What s Inside: 3 PAGE Get the facts, then get the cure 4 PAGE 9 PAGE 12 PAGE Learn how TB is spread Treatment for TB disease Talking to family and friends about
LONG TERM CARE ASSISTANT Course Syllabus
6111 E. Skelly Drive P. O. Box 477200 Tulsa, OK 74147-7200 LONG TERM CARE ASSISTANT Course Syllabus Course Number: THRP-0010A OHLAP Credit: No OCAS Code: 9324 Course Length: 75 Hours Career Cluster: Health
Review of Pharmacological Pain Management
Review of Pharmacological Pain Management CHAMP Activities are possible with generous support from The Atlantic Philanthropies and The John A. Hartford Foundation The WHO Pain Ladder The World Health Organization
Treatment with Apixaban
UW MEDICINE PATIENT EDUCATION Treatment with Apixaban Eliquis This handout explains the medicine apixaban, a drug that helps prevent blood clots. What is apixaban? Apixaban (brand name Eliquis) is an anticoagulant
Introduction to Atrial Fibrillation (AFib)
Introduction to Atrial Fibrillation (AFib) Learn About: 1. What is atrial fibrillation? 2. How will I feel? 3. Who gets AFib? 4. Risk of stroke 5. AFib treatment 6. How to live well with AFib 1. What is
DEPARTMENT OF HEALTH AND HUMAN SERVICES Y F9999 FINAL OBSERVATIONS F9999 N LICENSURE VIOLATIONS LICENSURE VIOLATIONS
CENTERS FOR MEDICARE & MEDICA SERVICES OMB NO. 0938-0391 (X1) PROVER/SUPPLIER/CLIA ENTIFICATION NUMBER: B. WING (X3) SURVE NAME OF PROVER OR SUPPLIER (X4) REGULATOR OR LSC ENTIFING INFORMATION) PROVER'S
a) Each facility shall have a medical record system that retrieves information regarding individual residents.
TITLE 77: PUBLIC HEALTH CHAPTER I: DEPARTMENT OF PUBLIC HEALTH SUBCHAPTER c: LONG-TERM CARE FACILITIES PART 300 SKILLED NURSING AND INTERMEDIATE CARE FACILITIES CODE SECTION 300.1810 RESIDENT RECORD REQUIREMENTS
NEW PATIENT CLINICAL INFORMATION FORM. Booth Gardner Parkinson s Care & Movement Disorders Center Evergreen Neuroscience Institute
NEW PATIENT CLINICAL INFORMATION FORM Booth Gardner Parkinson s Care & Movement Disorders Center Evergreen Neuroscience Institute Date: Name: Referring Doctor: How did you hear about us? NWPF Your Physician:
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FEC-T. Patient s first names. Date of birth.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FEC-T Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas
Atrial Fibrillation. Patient Information. 828361 Dec 19-12
Atrial Fibrillation Patient Information 828361 Dec 19-12 Contents Introduction 1 Treatment & decrease stroke options 2 Information for people who are taking warfarin (Coumadin ) 5 Information for people
Emergency Room (ER) Visits: A Family Caregiver s Guide
Family Caregiver Guide Emergency Room (ER) Visits: A Family Caregiver s Guide Your family member may someday have a medical emergency and need to go to a hospital Emergency Room (ER), which is also called
Tuberculosis and You A Guide to Tuberculosis Treatment and Services
Tuberculosis and You A Guide to Tuberculosis Treatment and Services Tuberculosis (TB) is a serious disease that can damage the lungs or other parts of the body like the brain, kidneys or spine. There are
X-Plain Hip Replacement Surgery - Preventing Post Op Complications Reference Summary
X-Plain Hip Replacement Surgery - Preventing Post Op Complications Reference Summary Introduction Severe arthritis in the hip can lead to severe pain and inability to walk. To relieve the pain and improve
MEDICATION GUIDE ELIQUIS (ELL eh kwiss) (apixaban) tablets
MEDICATION GUIDE ELIQUIS (ELL eh kwiss) (apixaban) tablets What is the most important information I should know about ELIQUIS? For people taking ELIQUIS for atrial fibrillation: People with atrial fibrillation
AC: Doxorubicin and Cyclophosphamide
PATIENT EDUCATION patienteducation.osumc.edu What is AC? It is the short name for the drugs used for this chemotherapy treatment. The two drugs you will receive during this treatment are Doxorubicin (Adriamycin
Lesson 2: Health Professions
Glossary 1. Bachelor s Degree: a 4-year degree from a college or university 2. Certification: some jobs require you to complete a training program or pass an exam to show that you have the knowledge to
Rehab and Restorative Critical Element Pathway
Use this pathway for a sampled resident who has had a lack of improvement in any areas of functional ability to determine if the resident received necessary rehabilitative services. Review the following
What Are Arrhythmias?
What Are Arrhythmias? Many people have questions about what the word arrhythmia means, and arrhythmias can be a difficult subject to understand. The text below should give you a better understanding of
Heart Attack: What You Need to Know
A WorkLife4You Guide Heart Attack: What You Need to Know What is a Heart Attack? The heart works 24 hours a day, pumping oxygen and nutrient-rich blood to the body. Blood is supplied to the heart through
MS Treatments Gilenya
1 MSology Essentials Series Gilenya (fingolimod) Developed by MSology with the invaluable assistance of multiple sclerosis nurse advisors: Trudy Campbell Dalhousie MS Research Unit, Capital Health, Halifax,
Rehabilitation Medicine Clinic. New Patient Questionnaire
Rehabilitation Medicine Clinic (Please complete this 5-page form and bring to your appointment.) Date Appt. Date Age Date of Birth Name Male Female Hand dominance: R L Home Address Home Phone ( ) Work
Through Thick and Thin
Through Thick and Thin Learning to Live with Warfarin South Denver Cardiology Associates PC What is Anticoagulation? Anti = against Coagulation = blood clotting An anticoagulant is a medication that reduces
LOEWENBERG SCHOOL OF NURSING LOEWENBERG SCHOOL OF NURSING HEALTH EXAMINATION FORM (FORM 003)
SECTION I: To be completed by STUDENT: Name: DOB: Address: Phone (H): Phone (C): Health History: Please complete the following information: Recent weight loss or gain Fatigue, fever, sweats Difficulty
What you should know about treating your pain with opioids. Important information on the safe use of opioid pain medicine.
What you should know about treating your pain with opioids Important information on the safe use of opioid pain medicine. If your healthcare provider has determined that opioid therapy is right for you,
WELCOME TO TRI-COUNTY EYE CLINIC
WELCOME TO TRI-COUNTY EYE CLINIC Thank you for choosing Tri-County Eye Clinic as the provider for your eye care. You have an appointment at one of the following two locations: 15122 Dedeaux Road, Gulfport,
Get the Facts About Tuberculosis Disease
TB Get the Facts About Tuberculosis Disease What s Inside: Read this brochure today to learn how to protect your family and friends from TB. Then share it with people in your life. 2 Contents Get the facts,
***************PATIENT INFORMATION****************
SEP BADY, MD ***************PATIENT INFORMATION**************** TODAYS DATE: / / WHICH DOCTOR ARE YOU SEEING? BADY KURUVILLA LIU OTTEN TRAINOR YEE PATIENT LAST NAME: FIRST: MIDDLE INITIAL: ADDRESS: CITY/STATE:
Atrial Fibrillation. Gibtsawit Kidane Kimberly Pullen Jennifer Smith
Atrial Fibrillation Gibtsawit Kidane Kimberly Pullen Jennifer Smith Background Our Patient D. B. is a 59 year old Caucasian male Successful business owner College educated New diagnosis of atrial fibrillation
Sentimental Journey. Ambulance Model Project
Sentimental Journey Ambulance Model Project The program is a collaborative effort between hospice organizations and EMS transport services to provide special trips to requested destinations for inhouse
MEDICATION GUIDE COUMADIN (COU-ma-din) (warfarin sodium)
MEDICATION GUIDE COUMADIN (COU-ma-din) (warfarin sodium) Read this Medication Guide before you start taking COUMADIN (warfarin sodium) and each time you get a refill. There may be new information. This
Ultrasound. PATIENT GUIDE and PREPARATION. Thoracentesis
Ultrasound PATIENT GUIDE and PREPARATION Thoracentesis What is a Thoracentesis? A Thoracentesis is a procedure that involves using a needle to drain fluid from either within the lungs or the surrounding
Let s Learn the Basics about Cervical Cancer
A Publication of the National Center for Farmworker Health October-December 2014 Let s Learn the Basics about Cervical Cancer What is cancer? The body is made up of millions and millions of living cells.
SUBSTANCE USE DISORDER SOCIAL DETOXIFICATION SERVICES [ASAM LEVEL III.2-D]
SUBSTANCE USE DISORDER SOCIAL DETOXIFICATION SERVICES [ASAM LEVEL III.2-D] I. Definitions: Detoxification is the process of interrupting the momentum of compulsive drug and/or alcohol use in an individual
DIABETES A chronic, debilitating and often deadly disease A global epidemic Diabetes in Africa
DIABETES A chronic, debilitating and often deadly disease Diabetes is a chronic condition that arises when the pancreas does not produce enough insulin, or when the body cannot effectively use the insulin
